Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220753302> ?p ?o ?g. }
- W4220753302 abstract "Janus kinase 2 (JAK2) hyperactivation by JAK2V617F mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promising therapeutic strategy for MPNs. Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays verified that FM had a stronger affinity for the pseudokinase domain JH2 than JH1 of JAK2 and had an inhibitory effect on JAK2 JH2V617F. The cocrystal structure confirmed that FM could stably bind to JAK2 JH2, and FM suppressed endogenous colony formation of primary erythroid progenitor cells from patients with MPNs. In several JAK2V617F-induced MPN murine models, FM could dose-dependently reduce hepatosplenomegaly and prolong survival. Similar results were observed in JAK2V617F bone marrow transplantation mice. FM exhibited strong inhibitory effects on fibrosis of the spleen and bone marrow. Long-term FM treatment showed good pharmacokinetic/pharmacodynamic characteristics with high drug exposure in tumor-bearing tissues and low toxicity. Currently, FM has been approved by the National Medical Products Administration of China (CXHL2000628), and this study will guide clinical trials for patients with MPNs." @default.
- W4220753302 created "2022-04-03" @default.
- W4220753302 creator A5005636511 @default.
- W4220753302 creator A5005772370 @default.
- W4220753302 creator A5021871801 @default.
- W4220753302 creator A5027269469 @default.
- W4220753302 creator A5031046349 @default.
- W4220753302 creator A5035978729 @default.
- W4220753302 creator A5039844914 @default.
- W4220753302 creator A5044863318 @default.
- W4220753302 creator A5047901608 @default.
- W4220753302 creator A5048186638 @default.
- W4220753302 creator A5051123510 @default.
- W4220753302 creator A5059148938 @default.
- W4220753302 creator A5077666079 @default.
- W4220753302 creator A5078099143 @default.
- W4220753302 creator A5081493442 @default.
- W4220753302 creator A5090743547 @default.
- W4220753302 date "2022-03-07" @default.
- W4220753302 modified "2023-10-10" @default.
- W4220753302 title "Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms" @default.
- W4220753302 cites W1523813197 @default.
- W4220753302 cites W1534089060 @default.
- W4220753302 cites W1964432512 @default.
- W4220753302 cites W1973160387 @default.
- W4220753302 cites W1980568348 @default.
- W4220753302 cites W1980574180 @default.
- W4220753302 cites W1995981641 @default.
- W4220753302 cites W2001215875 @default.
- W4220753302 cites W2008429932 @default.
- W4220753302 cites W2009176064 @default.
- W4220753302 cites W2029160308 @default.
- W4220753302 cites W2044410928 @default.
- W4220753302 cites W2049145190 @default.
- W4220753302 cites W2056171219 @default.
- W4220753302 cites W2057360098 @default.
- W4220753302 cites W2061377922 @default.
- W4220753302 cites W2079645940 @default.
- W4220753302 cites W2087701900 @default.
- W4220753302 cites W2093953283 @default.
- W4220753302 cites W2110210855 @default.
- W4220753302 cites W2114713566 @default.
- W4220753302 cites W2115351357 @default.
- W4220753302 cites W2120408260 @default.
- W4220753302 cites W2121743767 @default.
- W4220753302 cites W2122395736 @default.
- W4220753302 cites W2134540087 @default.
- W4220753302 cites W2138165161 @default.
- W4220753302 cites W2140359782 @default.
- W4220753302 cites W2144664431 @default.
- W4220753302 cites W2150673280 @default.
- W4220753302 cites W2164845217 @default.
- W4220753302 cites W2289879004 @default.
- W4220753302 cites W2318165535 @default.
- W4220753302 cites W2342067681 @default.
- W4220753302 cites W2583102591 @default.
- W4220753302 cites W2674575612 @default.
- W4220753302 cites W2759277150 @default.
- W4220753302 cites W2759579362 @default.
- W4220753302 cites W2805481066 @default.
- W4220753302 cites W2805489776 @default.
- W4220753302 cites W2806532950 @default.
- W4220753302 cites W2956179332 @default.
- W4220753302 cites W2957077159 @default.
- W4220753302 cites W2978551174 @default.
- W4220753302 cites W2984592214 @default.
- W4220753302 cites W3001373379 @default.
- W4220753302 cites W3005853243 @default.
- W4220753302 cites W3037233470 @default.
- W4220753302 cites W3041411480 @default.
- W4220753302 cites W3046413528 @default.
- W4220753302 cites W3128067841 @default.
- W4220753302 cites W3172890748 @default.
- W4220753302 doi "https://doi.org/10.1038/s41408-022-00628-2" @default.
- W4220753302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35256594" @default.
- W4220753302 hasPublicationYear "2022" @default.
- W4220753302 type Work @default.
- W4220753302 citedByCount "1" @default.
- W4220753302 countsByYear W42207533022023 @default.
- W4220753302 crossrefType "journal-article" @default.
- W4220753302 hasAuthorship W4220753302A5005636511 @default.
- W4220753302 hasAuthorship W4220753302A5005772370 @default.
- W4220753302 hasAuthorship W4220753302A5021871801 @default.
- W4220753302 hasAuthorship W4220753302A5027269469 @default.
- W4220753302 hasAuthorship W4220753302A5031046349 @default.
- W4220753302 hasAuthorship W4220753302A5035978729 @default.
- W4220753302 hasAuthorship W4220753302A5039844914 @default.
- W4220753302 hasAuthorship W4220753302A5044863318 @default.
- W4220753302 hasAuthorship W4220753302A5047901608 @default.
- W4220753302 hasAuthorship W4220753302A5048186638 @default.
- W4220753302 hasAuthorship W4220753302A5051123510 @default.
- W4220753302 hasAuthorship W4220753302A5059148938 @default.
- W4220753302 hasAuthorship W4220753302A5077666079 @default.
- W4220753302 hasAuthorship W4220753302A5078099143 @default.
- W4220753302 hasAuthorship W4220753302A5081493442 @default.
- W4220753302 hasAuthorship W4220753302A5090743547 @default.
- W4220753302 hasBestOaLocation W42207533021 @default.
- W4220753302 hasConcept C126322002 @default.
- W4220753302 hasConcept C170493617 @default.
- W4220753302 hasConcept C201750760 @default.